for Prostate Cancer

 

10,000+ Men Have Chosen Cesium-131
to Treat Their Prostate Cancer

Considering multiple treatment options?

Compare the leading treatments for Prostate Cancer and consult your doctor about your options.

   Acceptable side effects comparable to other treatments (1)

   Less impact on urinary function than surgery (1)

   Higher degree of sexual function reported at three year follow up(1)

   45 minutes to 1 hour for complete implant

   Hospitalization rarely required

   First ultrasound guided implant performed in 1985

   Local control rates up to 99% of patients in long term studies (5)

–  Very few GI or rectal side effects have been reported.

–  Higher degree of poor urinary function(1)

–  Higher degree of sexual dysfunction (1)

–  3-4 hours procedure

–  Up to a 4 day hospital stay

–  Early reports of robotic surgery began in 2003 (2)

–  83% local control rates achieved at high volume centers (4

–  Late rectal morbidity likely(3)

–  Urinary bother occurs in 12-40% of patients treated (3)

–  Approximately 78% of patients maintain sexual function (6)

–  Five days per week for up to nine weeks.

–  Hospitalization is rarely required

–  IMRT adaptation acceleration began in 2003

–  89% of patients in local control rates in long term study (3)

A Patient's Guide to Prostate Cancer

If you or a loved one has recently been diagnosed with prostate cancer and want to learn more, download our patient guide.

Learn more about the tests for prostate cancer.

  • Prostate Specific Antigen (PSA) Screening
  • Digital Rectal Exam (DRE)

Our Patient’s Stories

Brachytherapy Effectively Treats Prostate Cancer

Prostate brachytherapy with Cesium-131 places cancer-fighting medical radioisotopes in and/or around the prostate, as close to the cancer as possible.  The isotopes are encased in capsules the size of a grain of rice and release a personalized radiation dose over a period of days. This allows the effective treatment of the prostate while minimizing side effects and damage to nearby tissue.

A comprehensive review of the literature comparing risk stratified patients by treatment with long-term follow-up, Grimm et al, provided a visual comparison of different treatments for prostate cancer. 

Compare Your Options

Compare your treatment options with the help of ProstateCancerFree.org a non-profit founded by doctors who are passionate about helping men with prostate cancer.

Quality of Life

The short half life of Cesium-131 delivers treatment quickly to the patient, and allows the patient to recover quickly. As seen below, studies have shown that the patient IPSS will return to baseline faster than following brachytherapy with either Iodine and Palladium. This gives patients the opportunity to put treatment behind them, and move beyond their cancer.

Patients and Families

The Isoray team is here to help. Contact us below and our experts will help connect you with clinicians, researchers, and our support team to answer your questions about Isoray and Cesium-131.

Resources & Research

1. Benoit, et al., “Five Year Prostate Specific Antigen Outcomes after Cesium Brachytherapy”, Clin Onc, 26 (2014) 776-780.

2. Grimm, et al., “Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapyBJUI, 109S1, 2012 p 22-29.

3. ArmpillaC, Dale R, Coles I, et al. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Rad Onc Bio Phys 2003; 55:378-385.

4. Shah AB, et al. A Comparison of AUA Symptom Scores following Permanent Low-Dose-Rate Prostate Brachytherapy with Iodine-125 and Cesium-131.

5. Bice, W. “Permanent prostate brachytherapy using Cs-131 for localized prostatic carcinoma: a phase II study.” Presented at the 2008 Cesium Advisory Group Meeting November 2008. Tuscon, Arizona, U.S.A.

6. Keyes M, et al. “Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcomes in 712 consecutive patients.” International Journal of Radiation Oncology, Biology and Physics 73(4):1023-32, 2009.

7. Ash D, et al. “A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localized prostate cancer.” Radiotherapy and Oncology 84(2):145-9, 2007.

8. Jacobs BL, et al. Acute lower urinary tract symptoms after prostate brachytherapy with Cesium-131. Urology 75(5):1143-7, 2010.

9. Prestidge B.R., Bice W.S., Jurkovic I., et al. Cesium-131 Permanent Prostate Brachytherapy: An Initial Report. Int. J. Radiation Oncology Biol. Phys. 2005: 63 (1) 5336-5337.

10. Neill B, et al. The Nature and Extent of Urinary Morbidity in Relation to Prostate Brachytherapy Urethral Dosimetry. Brachytherapy 2007:6(3)173-9.

11. Musmacher JS, et al. Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy. Int. J. Radiation Oncology Biol. Phys. 2007:69(3)S730-1.

12. Yaparpalvi R, et al. Is Cs-131 or I-125 or Pd-103 the “Ideal” Isotope for Prostate Boost Brachytherapy? A Dosimetric View Point. Int. J. Radiation Oncology Biol. Phys. 2007:69(3)S677-8.

13. Sutlief S, et al. Cs-131 Prostate Brachytherapy and Treatment Plan Parameters. Medical Physics 2007:34(6)2431.

14. Yang R, et al. Dosimetric Comparison of Permanent Prostate Brachytherapy Plans Utilizing Cs-131, I-125 and Pd-103 Seeds. Medical Physics 2008:35(6)2734.

15. Prestidge B, et. al. Clinical Outcomes of a Phase-II, Multi-institutional Cesium-131 Permanent Prostate Brachytherapy Trial. Brachytherapy. 2007: 6 (2)78.

16. Moran B, et al. Cesium-131 Prostate Brachytherapy: An Early Experience. Brachytherapy 2007:6(2)80.

17. Jones A, et al. IPSS Trends for Cs-131 Permanent Prostate Brachytherapy. Brachytherapy 2008:7(2)194.

18. DeFoe SG, et al. Is There Decreased Duration of Acute Urinary and Bowel Symptoms after Prostate Brachytherapy with Cesium 131 Radioisotope? Int. J. Radiation Oncology Biol. Phys. 2008:72(S1)S317.

19. Bice W, et. al. Recommendations for permanent prostate brachytherapy with 131Cs: a consensus report from the Cesium Advisory Group. Brachytherapy 2008:7(4)290-296.

20. Platta CS, et al. Early Outcomes of Prostate Seed Implants with 131Cs: Toxicity and Initial PSA Dynamics from a Single Institution. Int. J. Radiation Oncology Biol. Phys. 2008:72(S1)S323-4.

View the Prostate Cancer Patient Guide from PCF.org

Every day patients around the world are treated with our cutting edge technologies.

Read and watch their stories and learn about the innovative doctors around the world helping patients.

Over 13,000+ patients have experienced the power of Cesium Blu for treating cancer.

Learn about the options for you, a friend, or a family member.

Prostate

Over 10,000 patients treated.

Brain

A novel approach for radiation delivery.

Gynecological

An innovative solution for recurrent cancers.

Head & Neck

Delivering personalized radiation to tightly controlled areas.

Lung

Customized individual cancer treatment.